Spark Therapeutics and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B
In addition to SPK-9001, Spark Therapeutics previously received breakthrough therapy designation for voretigene neparvovec, which is being developed for the potential treatment of inherited retinal ...




